Medigen shares COVID vaccine tech with WHO in world-first deal

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Medigen shares COVID vaccine tech with WHO in world-first deal

covid.jpg

The Taiwanese biotech firm is the first commercial entity to share IP and know-how via a WHO pool set up in 2020

Taiwanese biotech firm Medigen yesterday, August 29, became the first commercial entity to share COVID vaccine technology with the World Health Organization.

Medigen’s vaccine unit was among three licensors to share tech via the WHO’s COVID-19 Technology Access Pool (C-TAP) in new deals, alongside research institutes in Spain and Chile.

The deals involve the licensing of patents as well as the sharing of know-how, materials, and clinical data.

More than three million doses of Medigen's vaccine have been administered across seven countries.

The Spanish National Research Council (CSIC) agreed to share access to a COVID vaccine prototype while the University of Chile will share tech for a COVID antibody test.

“COVID-19 is here to stay, and the world will continue to need tools to prevent it, test for it and treat it,” said Tedros Adhanom Ghebreyesus, WHO director-general.

“I am grateful to the leadership shown by those licence holders who have contributed technology,” he added.

Charles Chen, CEO of Medigen Vaccine Biologics, said solidarity and cooperation were the foundations of an effective pandemic response.

“This is not just about COVID-19; it is about setting a precedent for future global health challenges.

“We hope to inspire other organisations to follow suit,” Chen said.

Previously, only two public health institutes – the CSIC, which signed a separate deal with C-TAP in 2021, and the US National Institute of Health – had agreed to license tech through the WHO pool since it was set up in 2020.

Access to medicine campaigners welcomed the news as a “significant step” and urged major COVID vaccine makers to share their intellectual property.

Julia Kosgei, policy co-lead for campaign group the People’s Vaccine Alliance, said: “By sharing technology with C-TAP, these organisations are placing the needs of humanity over the narrow perception of profit and self-interest that has so far plagued the pharmaceutical industry.”

“It is shameful that, despite receiving unprecedented public funding and advance purchases, not even one of the major pharmaceutical companies has shared vaccine technology with C-TAP,” Kosgei added.

Negotiations for a pandemic prevention treaty, including potential reforms to the global intellectual property system, are currently ongoing at the WHO.

more from across site and SHARED ros bottom lb

More from across our site

Jinwon Chun discusses the need for vigilance, his love for iced coffee, and preparing for INTA
Karl Barnfather’s new patent practice will focus on protecting and enforcing tech innovations in the electronics, AI, and software industries
Partner Ranjini Acharya explains how her Federal Circuit debut resulted in her convincing the court to rule that machine learning technology was not patent-eligible
Paul Hastings and Smart & Biggar also won multiple awards, while Baker McKenzie picked up a significant prize
Burford Capital study finds that in-house lawyers have become more likely to monetise patents, but that their IP portfolios are still underutilised
Robert Reading and Faidon Zisis at Clarivate unpick some of the data surrounding music-related trademarks
China's latest IP litigation statistics and a high-profile hire by O'Melveny were also among the top talking points this week
David Aylen, who spent more than 20 years at Gowling WLG, has joined United Trademark and Patent Services as of counsel in the UAE
Europe is among the most lucrative legal markets for PE firms to bet on, but clients’ reactions will decide whether external investment drives success
Rulings of note covered pre-June 2023 infringements and jurisdiction over non-UPC states, while winners of Managing IP’s EMEA Awards acted in multiple cases
Gift this article